Biodesix sells lung diagnostic tests to healthcare providers and testing services to drug developers. BDSX reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 13 | TD Cowen | Maintained | Buy | |
| Sep 28 | HC Wainwright & Co. | Target raised | Buy | |
| Aug 10 | Canaccord Genuity | Target raised | Buy | |
| Aug 6 | HC Wainwright & Co. | Target raised | Buy | |
| Jun 25 | Roth Capital | Initiated | Buy |
Seasonality
How BDSX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in BDSX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BDSX is in one of them and how their past BDSX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BDSX in an article yet. Here's the latest on the wider market.
About Biodesix
Biodesix is a diagnostic solutions company based in Louisville, Colorado. It sells blood based lung diagnostic tests to healthcare providers, helping them assess lung nodules and guide treatment for lung cancer patients. Its tests combine several technologies, including genomics, proteomics and radiomics, with artificial intelligence. It also offers diagnostic testing and consulting services to biopharmaceutical, life sciences and diagnostics companies.
- Headquarters
- Louisville, CO